Intuitive Surgical, Inc. (ISRG) $342.48
Intuitive Surgical is currently free-falling toward its 52-week low, leaving investors to wonder if the robotic surgery pioneer has lost its spark or if this is the ultimate entry window.
52-wk High $603.88
📌 Investment Snapshot
- Trading at $342.48, just 0.7% above its 52-week low of $340.72.
- Latest Q1 2026 revenue hit $2.77B with EPS of $2.31, showing resilient growth.
- Massive 43% discount from the 52-week high of $603.88 creates a valuation gap.
- Wall Street remains bullish with a $490.47 mean target and 28 ‘Buy’ ratings.
⏳ WAIT
ISRG is trapped in a violent downtrend that has erased 28% of its value in just three months. While the long-term thesis remains intact, the technical floor has not yet been established.
| 📍 Entry Zone | $335.00 or below | 🛑 Stop-Loss | $318.00 |
| 📋 Adjust If | reclaims the $355.00 FVG zone with high volume | ||
The Investment Case — Why Now?
Over the last 90 days, the narrative around Intuitive Surgical shifted from premium growth to macro-driven contraction. Despite consistent revenue beats, the stock is suffering from a multiple compression as the 10Y Treasury yield hovers at 4.66%.
The primary risk stems from a potential slowdown in capital expenditures by hospitals facing tighter credit conditions. If system placements drop by even 5% in the next quarter, the current 39x P/E could face another leg down toward the low 30s.
Do you believe the current 43% drawdown reflects a permanent shift in hospital spending or just a temporary macro headwind?
🤔 Do you believe the current 43% drawdown reflects a permanent shift in hospital spending or just a temporary macro headwind?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Instruments |
| CEO | David J. Rosa |
| Employees | 14,000+ |
Open chart on TradingView →
📈 Price Action & Technicals
Dead Cross
Outside VA
Buy-side Sweep at $397.52
The price is currently trading well below both the SMA50 ($410.78) and SMA200 ($485.15), confirming a strong bearish regime. A ‘Death Cross’ occurred weeks ago, and the gap between these averages continues to widen.
RSI at 33.6 signals significant weakness but has not yet hit the sub-30 level that historically triggers a sharp mean-reversion. The MACD histogram is expanding downward, suggesting that selling pressure has not reached exhaustion.
Price action is currently pinned below the Anchored VWAP of $346.07, which now acts as immediate overhead resistance. The Volume Profile shows a ‘high volume node’ at $409.14, meaning the stock is currently in a ‘liquidity vacuum’ with little support until the $324 low target.
Three bearish Fair Value Gaps (FVGs) remain open above $355, acting like magnets for a future relief rally. However, the recent sell-side sweeps indicate that institutions are not yet defending these lower levels with conviction.
Historically, when ISRG trades this far below its 200-day moving average, it stays depressed for 4-6 weeks before a sustainable bottom forms. We are currently in week three of this specific flush.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ISRG | Intuitive Surgical | 39.3x |
| SYK | Stryker Corp | 34.2x |
| MDT | Medtronic | 26.8x |
| SPX | S&P 500 Avg | 21.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $2.77B | $2.31 | +13.5% |
| Q4 2025 | $2.87B | $2.24 | +11.2% |
| Q3 2025 | $2.51B | $1.98 | +14.1% |
| Q2 2025 | $2.44B | $1.84 | +12.8% |
Intuitive generated $0.8B in Free Cash Flow last quarter, supporting a massive $1.1B buyback program. This aggressive capital return signals management’s belief that the shares are significantly undervalued at these levels.
Revenue growth remains remarkably consistent in the low double-digits, even as the stock price decouples from fundamentals. The divergence between a 13.5% revenue increase and a 43% price drop suggests the market is pricing in a severe recession that hasn’t appeared in the data yet.
🚀 Growth Drivers — What Moves the Stock
- Da Vinci 5 Adoption 🟢 Upside Surprise — The rollout of the next-gen system is driving higher ASPs and recurring instrument revenue.
- International Expansion 🟡 Priced In — Strong procedure growth in China and Japan is offsetting domestic hospital budget caution.
- Aggressive Buybacks 🟢 Upside Surprise — The $1.1B quarterly buyback reduces share count and provides an artificial floor for EPS.
🤔 If management is buying back $1.1B in stock, why are institutional investors still selling into the hole?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 30,075 |
| Vanguard Capital Management | 23,079 |
| State Street Corporation | 15,846 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| ROSA DAVID J | CEO | 2026-07-10 | Purchase | 1,910 |
| JEDDI IMAN | Officer | 2026-06-01 | Purchase | 5,625 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 2.1% | 2.8 |
⚠ Key Risk Factors
~$5B cap impact
~$12B cap impact
🎯 Guidance & Wall Street View
Management has maintained full-year procedure growth guidance of 14-17%, suggesting that the core business remains healthy despite the stock’s technical breakdown.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $685.00 | $490.47 | $324.00 | 28 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| JP Morgan | Overweight | $510 | 2026-07-17 | Maintained |
| Mizuho | Neutral | $380 | 2026-07-17 | Maintained |
Analysts are largely ignoring the price action, maintaining high targets based on 2027 earnings projections, creating a massive ‘valuation disconnect’.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Procedure growth exceeds 15% as Da Vinci 5 dominates the market.
- Fed begins rate cuts, sparking a massive rotation back into growth.
📊 Base Case
ISRG stabilizes near $340 and trades sideways until the October earnings report provides a clear catalyst.
🐻 Bear Case
- System placements miss estimates due to hospital budget cuts.
- Technical breakdown below $340 triggers a flush to $300.
🎯 Investor Action Plan — By Profile
Do not catch this falling knife. Wait for a daily close above the $346 VWAP or a bullish RSI divergence before playing for a bounce to the $393 FVG.
The Technical Confluence Score of 30 is too weak for a new entry. Let the stock test the $324 low target; if it holds, that becomes your high-conviction entry zone.
The fundamental story is unchanged. If you own it, hold through the volatility as the 39x P/E is the cheapest the stock has been in years relative to its growth.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why is ISRG stock falling if earnings are good?
The decline is driven by macro factors like high interest rates and a technical breakdown below key moving averages, rather than a failure in the business model.
Q: What is the key support level to watch?
The $340.72 level is critical; it is the 52-week low. A break below this could trigger a stop-loss cascade down to $324.
Q: Is the Da Vinci 5 system a failure?
No, early adoption data is strong. The stock price reflects market sentiment and valuation concerns, not the quality of the technology.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 How has the stock moved since this analysis?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. The author has no position in ISRG at the time of writing.
All active positions and their real-time performance are tracked on our Investment Log.
#ISRG #IntuitiveSurgical #RoboticSurgery #StockMarket #Investing #HealthcareStocks #TechnicalAnalysis #WallStreet